Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “infigratinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 11
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 11 pipeline programs matching "infigratinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

11 results for “infigratinib” Back to intelligence hub

Search results

  1. Infigratinib

    BridgeBio Oncology Therapeutics

    Upper Tract Urothelial Carcinomas

    phase 3 small molecule terminated

    1 trial
  2. Infigratinib 0.25 mg/kg/day

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 3 small molecule completed

    1 trial
  3. infigratinib 0.128 mg/kg/day

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 3 small molecule active

    1 trial
  4. BGJ398 (infigratinib)

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial
  5. Infigratinib

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial
  6. Infigratinib

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 2 small molecule active

    1 trial
  7. Infigratinib 0.016 mg/kg

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule completed

    1 trial
  8. Infigratinib is provided as a single dose of minitablets for oral administration

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial
  9. Infigratinib

    BridgeBio Oncology Therapeutics

    Glioma

    phase 1 small molecule terminated

    1 trial
  10. Infigratinib

    BridgeBio Oncology Therapeutics

    Bladder Transitional Cell Carcinoma

    phase 1 small molecule terminated

    1 trial
  11. Infigratinib

    BridgeBio Oncology Therapeutics

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.